Turn Therapeutics Reports Q3 2026 Net Loss of $6.2 Million
Turn Therapeutics (TTRX) reported a Q3 2026 net loss of $6.2M, or $0.21 per share, with $10.4M in cash. It expects funds to last until Q3 2027. The company reported progress in its atopic dermatitis program and plans to start a hidradenitis suppurativa trial in early 2027. GX-03 showed positive results in a Stage 1 atopic dermatitis trial, with 59.3% of patients achieving clear or almost clear skin after four weeks.
How this was made

The 30-second read
Why it matters
The disclosed loss and cash balance suggest near‑term financing risk, but upcoming trial readouts could change the narrative.
Market read
Micro‑cap biotech earnings with trial updates; relevant for investors tracking early‑stage biotech risk/reward.
What to watch
Potential value from upcoming atopic dermatitis and hidradenitis suppurativa trial data not yet priced in.
Background
Turn Therapeutics is a clinical‑stage biotech focused on dermatology treatments. The Q3 2026 filing is its first earnings release for the year.
Ticker impact
Turn Therapeutics disclosed Q3 2026 results with a net loss of $6.2M and cash runway to Q3 2027, plus trial updates.
likely downward pressure as investors price in the loss and limited cash runway
Micro‑cap biotech earnings that miss expectations typically trigger sell‑offs, especially with a small cash balance.
Market effects
Highlights ongoing risk in early‑stage biotech sector and may dampen sentiment for similar dermatology‑focused firms.
Limited to US biotech investors; no broader regional effect.
Minimal global impact; primarily relevant to niche biotech investors.
Counterpoint
Some investors may view the cash runway to 2027 as a runway for upcoming trial readouts and could see upside.
Key entities
- companyTurn Therapeutics
Clinical‑stage biotech developing GX-03 for skin disorders.
- personRobert R. Redfield, M.D.
Appointed chief scientific officer, former CDC director.